

**For Release: Friday November 13, 2009**

Contact: Dr. Laura Strong, President and Chief Operating Officer, 608-441-2950

### **Quintessence Biosciences to Present QBI-139 Data at International AACR-NCI-EORTC Conference**

BOSTON, MA AND MADISON, WI –Quintessence Biosciences, Inc. today announced that it will present new data from nonclinical studies of QBI-139 at the upcoming International Conference on Molecular Targets and Cancer Therapeutics, which is being held in Boston, MA from November 15-19, 2009. QBI-139 is the most advanced candidate from the EVade™ Ribonuclease technology platform and is currently in a Phase I clinical trial. The data (abstract C42) will be presented in the clinical trials 3 session on Wednesday November 18, 2009 12:30 PM - 2:30 PM.

### **About Quintessence Biosciences, Inc.**

Quintessence Biosciences, Inc. is a private biopharmaceutical company focused on development of proprietary cancer therapies based on the EVade™ Ribonuclease technology. Quintessence's first product candidate, QBI- 139, is in a Phase 1 clinical trial at the University of Wisconsin Comprehensive Cancer Center. The company also has a pipeline of other EVade™ Ribonuclease products in preclinical research. For more information, visit [www.quintbio.com](http://www.quintbio.com).

### **About QBI-139**

QBI-139 is a potent anticancer agent based on the EVade™ Ribonuclease technology. The technology provides an opportunity to attack RNA, an exciting new drug target, in cancer cells with analogs of the human pancreatic ribonuclease 1. In preclinical disease models, QBI-139 has shown a strong tolerability profile and outstanding tumor growth inhibition *in vivo* against human colorectal, pancreatic, non-small cell lung, prostate, and ovarian solid tumors. QBI-139 is currently in a solid tumors Phase I human clinical trial.

### **About the International Conference on Molecular Targets and Cancer Therapeutics**

Three of the world's leading cancer organizations:

- The European Organization for Research and Treatment of Cancer
- The USA's National Cancer Institute
- The American Association for Cancer Research

will provide a forum for delegates from all over the world to discuss innovation in drug development, target selection and the impact of new discoveries in molecular and cell biology. The meeting will be held in Boston, Massachusetts from November 15-19, 2009.

<http://www.aacr.org/home/scientists/meetings--workshops/molecular-targets-and-cancer-therapeutics.aspx>